Roles of enhancer of zeste homolog 2: From skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis

Cell Cycle

Volumn 13, Issue 4, 2014, Pages 516-527

  Marchesi, Irene ^a   Giordano, Antonio ^b,c   Bagella, Luigi ^a,b  

^a UNIVERSITY OF SASSARI   (Italy)

^b Temple University   (United States)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Cancer epigenetics; Differentiation; EZH2; Myogenesis; Polycomb group proteins; Rhabdomyosarcoma

Indexed keywords

ATROGIN 1; BMI1 PROTEIN; CHAPERONE; HISTONE CHAPERONE SPT6; LONG UNTRANSLATED RNA; MICRORNA 214; MICRORNA 29A; MYOD PROTEIN; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; HISTONE; MICRORNA;

BINDING AFFINITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL RENEWAL; DEMETHYLATION; DISEASE ASSOCIATION; EMBRYONIC STEM CELL; EPIGENETIC REPRESSION; GENE SILENCING; MUSCLE DEVELOPMENT; NONHUMAN; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TURNOVER TIME; ANIMAL; CYTOLOGY; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; GENE SILENCING; HISTONES; HUMANS; MICRORNAS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; RHABDOMYOSARCOMA;

EID: 84896858736     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27921     Document Type: Review

References (167)

1. Van Speybroeck L. From epigenesis to epigenetics: the case of C. H. Waddington. Ann N Y Acad Sci 2002; 981:61-81; PMID:12547674; http://dx.doi.org/10.1111/j.1749-6632.2002.tb04912.x
2. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4:143-53; PMID:14732866; http://dx.doi.org/10.1038/nrc1279
3. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447:407-12; PMID:17522673; http://dx.doi.org/10. 1038/nature05915
4. Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol 2009; 10:192-206; PMID:19234478; http://dx.doi.org/10.1038/nrm2640
5. Fiorentino FP, Marchesi I, Giordano A. On the role of retinoblastoma family proteins in the establishment and maintenance of the epigenetic landscape. J Cell Physiol 2013; 228:276-84; PMID:22718354; http://dx.doi.org/10. 1002/jcp.24141
6. Marchesi I, Bagella L. Role of Enhancer of Zeste Homolog 2 Polycomb Protein and Its Significance in Tumor Progression and Cell Differentiation. In: Radzioch D, editor. InTech; 2013.
7. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7:21-33; PMID:16369569; http://dx.doi.org/10. 1038/nrg1748
8. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; http://dx.doi.org/10.1016/j.cell.2007.01.029
9. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-98; PMID:17339880; http://dx.doi.org/10.1038/ nrg2005
10. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400; PMID:15765097; http://dx.doi.org/10.1038/ng1531
11. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435:1262-6; PMID:15988529; http://dx.doi.org/10.1038/nature03672
12. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647:21-9; PMID:18723033; http://dx.doi.org/10. 1016/j.mrfmmm.2008.07.010
13. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz CC, Otte AP, Panning B, Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science 2003; 300:131-5; PMID:12649488; http://dx.doi.org/10. 1126/science.1084274
14. Umlauf D, Goto Y, Cao R, Cerqueira F, Wagschal A, Zhang Y, Feil R. Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet 2004; 36:1296-300; PMID:15516932; http://dx.doi.org/10.1038/ng1467
15. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441:349-53; PMID:16625203; http://dx.doi.org/10.1038/nature04733
16. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125:301-13; PMID:16630818; http://dx.doi.org/10.1016/j.cell.2006.02.043
17. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20:1123-36; PMID:16618801; http://dx.doi.org/10.1101/gad.381706
18. Pietersen AM, van Lohuizen M. Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol 2008; 20:201-7; PMID:18291635; http://dx.doi.org/10.1016/j.ceb.2008.01.004
19. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6:846-56; PMID:17060944; http://dx.doi.org/10.1038/nrc1991
20. Schwartz YB, Kahn TG, Nix DA, Li X-Y, Bourgon R, Biggin M, Pirrotta V. Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nat Genet 2006; 38:700-5; PMID:16732288; http://dx.doi.org/10.1038/ng1817
21. Nègre N, Hennetin J, Sun LV, Lavrov S, Bellis M, White KP, Cavalli G. Chromosomal distribution of PcG proteins during Drosophila development. PLoS Biol 2006; 4:e170; PMID:16613483; http://dx.doi.org/10.1371/journal.pbio. 0040170
22. Tolhuis B, de Wit E, Muijrers I, Teunissen H, Talhout W, van Steensel B, van Lohuizen M. Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in Drosophila melanogaster. Nat Genet 2006; 38: 694-9; PMID:16628213; http://dx.doi.org/10.1038/ng1792
23. Oktaba K, Gutiérrez L, Gagneur J, Girardot C, Sengupta AK, Furlong EEM, Müller J. Dynamic regulation by polycomb group protein complexes controls pattern formation and the cell cycle in Drosophila. Dev Cell 2008; 15:877-89; PMID:18993116; http://dx.doi.org/10.1016/j.devcel.2008.10.005
24. Schuettengruber B, Cavalli G. Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development 2009; 136:3531-42; PMID:19820181; http://dx.doi.org/10.1242/dev.033902
25. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010; 35:323-32; PMID:20346678; http://dx.doi.org/10.1016/j.tibs.2010.02.009
26. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469:343-9; PMID:21248841; http://dx.doi.org/10.1038/nature09784
27. Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W, Kingston RE. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 1999; 98:37-46; PMID:10412979; http://dx.doi.org/10.1016/S0092-8674(00)80604-2
28. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298:1039-43; PMID:12351676; http://dx.doi.org/10.1126/science. 1076997
29. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111:185-96; PMID:12408863; http://dx.doi.org/10.1016/S0092-8674(02)00975-3
30. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16:2893-905; PMID:12435631; http://dx.doi.org/10.1101/gad.1035902
31. Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE, Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111:197-208; PMID:12408864; http://dx.doi.org/10.1016/S0092-8674(02)00976-5
32. Surface LE, Thornton SR, Boyer LA. Polycomb group proteins set the stage for early lineage commitment. Cell Stem Cell 2010; 7:288-98; PMID:20804966; http://dx.doi.org/10.1016/j.stem.2010.08.004
33. Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science 2004; 306:1574-7; PMID:15567868; http://dx.doi.org/10.1126/science.1100576
34. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10:697-708; PMID:19738629
35. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004; 15:57-67; PMID:15225548; http://dx.doi.org/10.1016/j.molcel.2004.06.020
36. Pasini D, Bracken AP, Helin K. Polycomb group proteins in cell cycle progression and cancer. Cell Cycle 2004; 3:396-400; PMID:14752272; http://dx.doi.org/10.4161/cc.3.4.773
37. Abel KJ, Brody LC, Valdes JM, Erdos MR, McKinley DR, Castilla LH, Merajver SD, Couch FJ, Friedman LS, Ostermeyer EA, et al. Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1. Genomics 1996; 37:161-71; PMID:8921387; http://dx.doi.org/10.1006/geno.1996.0537
38. Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, Dynlacht BD, Reinberg D. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008; 32:503-18; PMID:19026781; http://dx.doi.org/10.1016/ j.molcel.2008.11.004
39. Shen X, Liu Y, Hsu Y-J, Fujiwara Y, Kim J, Mao X, Yuan GC, Orkin SH. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32:491-502; PMID:19026780; http://dx.doi.org/10.1016/j.molcel.2008.10.016
40. Stojic L, Jasencakova Z, Prezioso C, Stützer A, Bodega B, Pasini D, Klingberg R, Mozzetta C, Margueron R, Puri PL, et al. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. Epigenetics Chromatin 2011; 4:16; PMID:21892963; http://dx.doi.org/10.1186/1756-8935-4-16
41. Mousavi K, Zare H, Wang AH, Sartorelli V. Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol Cell 2012; 45:255-62; PMID:22196887; http://dx.doi.org/10.1016/j.molcel.2011.11.019
42. Leeb M, Pasini D, Novatchkova M, Jaritz M, Helin K, Wutz A. Polycomb complexes act redundantly to repress genomic repeats and genes. Genes Dev 2010; 24:265-76; PMID:20123906; http://dx.doi.org/10.1101/gad.544410
43. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, Presser A, Nusbaum C, Xie X, Chi AS, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4:e1000242; PMID:18974828; http://dx.doi.org/10.1371/journal.pgen.1000242
44. Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS. Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 2004; 14:637-46; PMID:15175158; http://dx.doi.org/10.1016/j.molcel.2004.05.009
45. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005; 20:845-54; PMID:16359901; http://dx.doi.org/10.1016/j.molcel.2005.12.002
46. Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D, Gilbert N, Fan Y, Skoultchi AI, Wutz A, et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell 2010; 38:452-64; PMID:20471950; http://dx.doi.org/10.1016/j.molcel.2010.02.032
47. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2011; 2:e204-7; PMID:21881606; http://dx.doi.org/10.1038/cddis.2011.84
48. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden J-M, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439:871-4; PMID:16357870; http://dx.doi.org/10.1038/nature04431
49. van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999; 23:474-8; PMID:10581039; http://dx.doi.org/10.1038/70602
50. Müller H, Bracken APA, Vernell R, Moroni MCM, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JDJ, Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 2001; 15:267-85; PMID:11159908; http://dx.doi.org/10.1101/ gad.864201
51. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22:5323-35; PMID:14532106; http://dx.doi.org/10.1093/emboj/ cdg542
52. Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008; 214:295-300; PMID:17786943; http://dx.doi.org/10.1002/jcp.21241
53. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2:669-83; PMID:21941025
54. Aldiri I, Vetter ML. PRC2 during vertebrate organogenesis: a complex in transition. Dev Biol 2012; 367:91-9; PMID:22565092; http://dx.doi.org/10.1016/j. ydbio.2012.04.030
55. Neri F, Zippo A, Krepelova A, Cherubini A, Rocchigiani M, Oliviero S. Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol Cell Biol 2012; 32:840-51; PMID:22184065; http://dx.doi.org/10.1128/MCB.06148-11
56. Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Int J Cancer 2013; 133:267-74; PMID:23001607; http://dx.doi.org/10.1002/ijc.27859
57. Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, Fusco A. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab 2012; 97:E710-8; PMID:22399519; http://dx.doi.org/10. 1210/jc.2011-3068
58. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012; 7:e33729; PMID:22442719; http://dx.doi.org/10.1371/journal.pone.0033729
59. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14:369-81; PMID:18977326; http://dx.doi.org/10.1016/j.ccr.2008.10.006
60. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8:172-5; PMID:19106613; http://dx.doi.org/10.4161/cc.8.1.7292
61. Riising EM, Boggio R, Chiocca S, Helin K, Pasini D. The polycomb repressive complex 2 is a potential target of SUMO modifications. PLoS One 2008; 3:e2704; PMID:18628979; http://dx.doi.org/10.1371/journal.pone.0002704
62. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010; 12:1108-14; PMID:20935635; http://dx.doi.org/10.1038/ncb2116
63. Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA, Reinberg D. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev 2010; 24:2615-20; PMID:21123648; http://dx.doi.org/10.1101/gad.1983810
64. Caretti G, Palacios D, Sartorelli V, Puri PL. Phosphoryl-EZH-ion. Cell Stem Cell 2011; 8:262-5; PMID:21362566; http://dx.doi.org/10.1016/j.stem.2011. 02.012
65. Zeng X, Chen S, Huang H. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Cell Cycle 2011; 10:579-83; PMID:21278485; http://dx.doi.org/10.4161/cc.10.4.14722
66. Wei Y, Chen Y-H, Li L-Y, Lang J, Yeh S-P, Shi B, Yang CC, Yang JY, Lin CY, Lai CC, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 2011; 13:87-94; PMID:21131960; http://dx.doi.org/10.1038/ ncb2139
67. Cha T-LT, Zhou BPB, Xia W, Wu Y, Yang C-CC, Chen C-TC, Ping B, Otte APA, Hung M-CM. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005; 310:306-10; PMID:16224021; http://dx.doi.org/ 10.1126/science.1118947
68. Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, Marquez VE, Valente S, Mai A, Forcales SV, et al. TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010; 7:455-69; PMID:20887952; http://dx.doi.org/10.1016/j.stem.2010.08.013
69. Yu Y-L, Chou R-H, Shyu W-C, Hsieh S-C, Wu C-S, Chiang S-Y, Chang WJ, Chen JN, Tseng YJ, Lin YH, et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol Med 2013; 5:531-47; PMID:23526793; http://dx.doi.org/10.1002/emmm. 201201783
70. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ 3rd, Voigt P, Martin SR, Taylor WR, De Marco V, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009; 461:762-7; PMID:19767730; http://dx.doi.org/10.1038/nature08398
71. Müller J, Kassis JA. Polycomb response elements and targeting of Polycomb group proteins in Drosophila. Curr Opin Genet Dev 2006; 16:476-84; PMID:16914306; http://dx.doi.org/10.1016/j.gde.2006.08.005
72. Ringrose L, Paro R. Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development 2007; 134:223-32; PMID:17185323; http://dx.doi.org/10.1242/dev.02723
73. Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, Margueron R, Reinberg D, Green R, Farnham PJ. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 2006; 16:890-900; PMID:16751344; http://dx.doi.org/10.1101/gr.5306606
74. Van Dessel N, Beke L, Görnemann J, Minnebo N, Beullens M, Tanuma N, Shima H, Van Eynde A, Bollen M. The phosphatase interactor NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at Polycomb targets. Nucleic Acids Res 2010; 38:7500-12; PMID:20671031; http://dx.doi.org/10.1093/nar/gkq643
75. Minnebo N, Görnemann J, O'Connell N, Van Dessel N, Derua R, Vermunt MW, Page R, Beullens M, Peti W, Van Eynde A, et al. NIPP1 maintains EZH2 phosphorylation and promoter occupancy at proliferation-related target genes. Nucleic Acids Res 2013; 41:842-54; PMID:23241245; http://dx.doi.org/10.1093/nar/ gks1255
76. Cakouros D, Isenmann S, Cooper L, Zannettino A, Anderson P, Glackin C, Gronthos S. Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells. Mol Cell Biol 2012; 32:1433-41; PMID:22290439; http://dx.doi.org/10.1128/MCB.06315-11
77. Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol Cell Biol 2008; 28:2718-31; PMID:18285464; http://dx.doi.org/10.1128/MCB.02017-07
78. Cao R, Wang H, He J, Erdjument-Bromage H, Tempst P, Zhang Y. Role of hPHF1 in H3K27 methylation and Hox gene silencing. Mol Cell Biol 2008; 28:1862-72; PMID:18086877; http://dx.doi.org/10.1128/MCB.01589-07
79. Corvetta D, Chayka O, Gherardi S, D'Acunto CW, Cantilena S, Valli E, Piotrowska I, Perini G, Sala A. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. J Biol Chem 2013; 288:8332-41; PMID:23362253; http://dx.doi.org/10.1074/jbc.M113.454280
80. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A, Wysocka J. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 2009; 139:1290-302; PMID:20064375; http://dx.doi.org/10.1016/j.cell.2009.12.002
81. Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, Mysliwiec MR, Yuan G-C, Lee Y, Orkin SH. Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 2009; 139:1303-14; PMID:20064376; http://dx.doi.org/10.1016/j.cell.2009.12.003
82. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 2010; 24:368-80; PMID:20123894; http://dx.doi.org/10.1101/gad.1886410
83. Pasini D, Cloos PAC, Walfridsson J, Olsson L, Bukowski J-P, Johansen JV, Bak M, Tommerup N, Rappsilber J, Helin K. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 2010; 464:306-10; PMID:20075857; http://dx.doi.org/10.1038/nature08788
84. Kerppola TK. Polycomb group complexes - many combinations, many functions. Trends Cell Biol 2009; 19:692-704; PMID:19889541; http://dx.doi.org/10.1016/j.tcb.2009.10.001
85. Bracken AP, Helin K. Epigenetics and genetics: Polycomb group proteins: navigators of lineage pathways led astray in cancer. 2009; 9: 773-84
86. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 2009; 106:11667-72; PMID:19571010; http://dx.doi.org/10.1073/pnas.0904715106
87. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-23; PMID:17604720; http://dx.doi.org/10.1016/j.cell.2007.05.022
88. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-6; PMID:14576434; http://dx.doi.org/10.1126/science.1088759
89. Wang L, Zeng X, Chen S, Ding L, Zhong J, Zhao JC, Wang L, Sarver A, Koller A, Zhi J, et al. BRCA1 is a negative modulator of the PRC2 complex. EMBO J 2013; 32:1584-97; PMID:23624935; http://dx.doi.org/10.1038/emboj.2013.95
90. Gil J, Bernard D, Martínez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004; 6:67-72; PMID:14647293; http://dx.doi.org/10.1038/ncb1077
91. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M, Marino S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004; 428:337-41; PMID:15029199; http://dx.doi.org/10.1038/nature02385
92. Bruggeman SWM, Valk-Lingbeek ME, van der Stoop PP, Jacobs JJ, Kieboom K, Tanger E, Hulsman D, Leung C, Arsenijevic Y, Marino S, et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005; 19:1438-43; PMID:15964995; http://dx.doi.org/10.1101/gad.1299305
93. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006; 7:667-77; PMID:16921403; http://dx.doi.org/10.1038/nrm1987
94. Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J, Helin K, Hansen KH. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J 2007; 26:1637-48; PMID:17332741; http://dx.doi.org/10.1038/sj.emboj.7601632
95. Chen H, Gu X, Su I-H, Bottino R, Contreras JL, Tarakhovsky A, Kim SK. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev 2009; 23:975-85; PMID:19390090; http://dx.doi.org/10.1101/gad.1742509
96. Dhawan S, Tschen SI, Bhushan A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev 2009; 23:906-11; PMID:19390085; http://dx.doi.org/10.1101/gad.1742609
97. Aoki R, Chiba T, Miyagi S, Negishi M, Konuma T, Taniguchi H, Ogawa M, Yokosuka O, Iwama A. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol 2010; 52:854-63; PMID:20395008; http://dx.doi.org/10.1016/j.jhep.2010. 01.027
98. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su I-H, Hannon G, Tarakhovsky A, Fuchs E. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009; 136:1122-35; PMID:19303854; http://dx.doi.org/10.1016/j.cell.2008.12.043
99. Shore AN, Kabotyanski EB, Roarty K, Smith MA, Zhang Y, Creighton CJ, Dinger ME, Rosen JM. Pregnancy-induced noncoding RNA (PINC) associates with polycomb repressive complex 2 and regulates mammary epithelial differentiation. PLoS Genet 2012; 8:e1002840; PMID:22911650; http://dx.doi.org/10.1371/journal. pgen.1002840
100. Sher F, Rössler R, Brouwer N, Balasubramaniyan V, Boddeke E, Copray S. Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. Stem Cells 2008; 26:2875-83; PMID:18687996; http://dx.doi.org/10.1634/stemcells.2008-0121
101. Sher F, Boddeke E, Copray S. Ezh2 expression in astrocytes induces their dedifferentiation toward neural stem cells. Cell Reprogram 2011; 13:1-6; PMID:20979531; http://dx.doi.org/10.1089/cell.2010.0052
102. Hirabayashi Y, Suzki N, Tsuboi M, Endo TA, Toyoda T, Shinga J, Koseki H, Vidal M, Gotoh Y. Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. Neuron 2009; 63:600-13; PMID:19755104; http://dx.doi.org/10.1016/j.neuron.2009.08.021
103. Pereira JD, Sansom SN, Smith J, Dobenecker M-W, Tarakhovsky A, Livesey FJ. Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A 2010; 107:15957-62; PMID:20798045; http://dx.doi.org/10.1073/pnas.1002530107
104. Wang L, Jin Q, Lee JE, Su I-H, Ge K. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci U S A 2010; 107:7317-22; PMID:20368440; http://dx.doi.org/10.1073/pnas.1000031107
105. Delgado-Olguín P, Huang Y, Li X, Christodoulou D, Seidman CE, Seidman JG, Tarakhovsky A, Bruneau BG. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet 2012; 44:343-7; PMID:22267199; http://dx.doi.org/10.1038/ ng.1068
106. Chen L, Ma Y, Kim EY, Yu W, Schwartz RJ, Qian L, Wang J. Conditional ablation of Ezh2 in murine hearts reveals its essential roles in endocardial cushion formation, cardiomyocyte proliferation and survival. PLoS One 2012; 7:e31005; PMID:22312437; http://dx.doi.org/10.1371/journal.pone.0031005
107. Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle 2013; 12:2042-50; PMID:23759596; http://dx.doi.org/10.4161/cc.25065
108. Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CCR, Hornyak TJ. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res 2011; 9:418-29; PMID:21383005; http://dx.doi.org/10.1158/1541-7786.MCR-10-0511
109. Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, Zhao RCH. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med (Maywood) 2012; 237:1110-6; PMID:22956625; http://dx.doi.org/10.1258/ebm. 2012.012075
110. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280:22437-44; PMID:15817459; http://dx.doi.org/10.1074/jbc. M501379200
111. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010; 17:801-10; PMID:19893569; http://dx.doi.org/10.1038/cdd.2009.162
112. Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M, Haberler C, Aronica E, Vandertop WP, Noske DP, et al. EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. Clin Cancer Res 2012; 18:4048-58; PMID:22696229; http://dx.doi.org/10.1158/1078-0432. CCR-12-0399
113. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 2013; 49:80-93; PMID:23159737
114. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004; 18:1592-605; PMID:15231737; http://dx.doi.org/10.1101/gad.1200204
115. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-5; PMID:20081860; http://dx.doi.org/10.1038/ng. 518
116. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010; 107:20980-5; PMID:21078963; http://dx.doi.org/10.1073/pnas.1012525107
117. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-6; PMID:20601953; http://dx.doi.org/10.1038/ng.621
118. Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tönnissen ERLTM, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42:665-7; PMID:20601954; http://dx.doi.org/10.1038/ng.620
119. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, Saunthararajah Y, Guinta K, Keddache MA, Putnam P, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24:1799-804; PMID:20724984; http://dx.doi.org/10.1038/leu.2010.167
120. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496-506; PMID:21714648; http://dx.doi.org/10.1056/NEJMoa1013343
121. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118:5227-34; PMID:21921040; http://dx.doi.org/10.1182/blood-2011-06-363424
122. Tatton-Brown K, Hanks S, Ruark E, Zachariou A, Duarte SdelV, Ramsay E, Snape K, Murray A, Perdeaux ER, Seal S, et al.; Childhood Overgrowth Collaboration. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget 2011; 2:1127-33; PMID:22190405
123. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298-301; PMID:22237151; http://dx.doi.org/10.1038/nm. 2651
124. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481:157-63; PMID:22237106; http://dx.doi.org/10.1038/nature10725
125. Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J Cell Physiol 2000; 185:155-73; PMID:11025438; http://dx.doi.org/10.1002/1097- 4652(200011)185:2〈155::AID-JCP1〉3.0.CO;2-Z
126. Bergstrom DA, Penn BH, Strand A, Perry RL, Rudnicki MA, Tapscott SJ. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Mol Cell 2002; 9:587-600; PMID:11931766; http://dx.doi.org/10.1016/S1097-2765(02)00481-1
127. Simone C, Forcales SV, Hill DA, Imbalzano AN, Latella L, Puri PL. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat Genet 2004; 36:738-43; PMID:15208625; http://dx.doi.org/10.1038/ng1378
128. Giacinti C, Bagella L, Puri PL, Giordano A, Simone C. MyoD recruits the
129. Marchesi I, Nieddu V, Caracciolo V, Maioli M, Gaspa L, Giordano A, Bagella L. Activation and function of murine Cyclin T2A and Cyclin T2B during skeletal muscle differentiation. J Cell Biochem 2013; 114:728-34; PMID:23060074; http://dx.doi.org/10.1002/jcb.24414
130. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004; 18:2627-38; PMID:15520282; http://dx.doi.org/ 10.1101/gad.1241904
131. Agger K, Cloos PAC, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E, Salcini AE, Helin K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007; 449:731-4; PMID:17713478; http://dx.doi.org/10.1038/nature06145
132. Hong S, Cho Y-W, Yu L-R, Yu H, Veenstra TD, Ge K. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A 2007; 104:18439-44; PMID:18003914; http://dx.doi.org/10.1073/ pnas.0707292104
133. Lan F, Bayliss PE, Rinn JL, Whetstine JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E, et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 2007; 449:689-94; PMID:17851529; http://dx.doi.org/10.1038/nature06192
134. Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L, Shiekhattar R. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 2007; 318:447-50; PMID:17761849; http://dx.doi.org/10. 1126/science.1149042
135. Ni Z, Saunders A, Fuda NJ, Yao J, Suarez J-R, Webb WW, Lis JT. P-TEFb is critical for the maturation of RNA polymerase II into productive elongation in vivo. Mol Cell Biol 2008; 28:1161-70; PMID:18070927; http://dx.doi.org/10.1128/ MCB.01859-07
136. Seenundun S, Rampalli S, Liu Q-C, Aziz A, Palii C, Hong S, Blais A, Brand M, Ge K, Dilworth FJ. UTX mediates demethylation of H3K27me3 at muscle-specific genes during myogenesis. EMBO J 2010; 29:1401-11; PMID:20300060; http://dx.doi.org/10.1038/emboj.2010.37
137. Wang AH, Zare H, Mousavi K, Wang C, Moravec CE, Sirotkin HI, Ge K, Gutierrez-Cruz G, Sartorelli V. The histone chaperone Spt6 coordinates histone H3K27 demethylation and myogenesis. EMBO J 2013; 32:1075-86; PMID:23503590; http://dx.doi.org/10.1038/emboj.2013.54
138. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell 2009; 36:61-74; PMID:19818710; http://dx.doi.org/10.1016/j. molcel.2009.08.008
139. Wong CF, Tellam RL. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 2008; 283:9836-43; PMID:18281287; http://dx.doi.org/10.1074/jbc.M709614200
140. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007; 27:4374-87; PMID:17438126; http://dx.doi.org/10.1128/MCB.02020-06
141. Sherwood RI, Christensen JL, Conboy IM, Conboy MJ, Rando TA, Weissman IL, Wagers AJ. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 2004; 119:543-54; PMID:15537543; http://dx.doi.org/10.1016/j.cell.2004.10.021
142. Collins CA, Olsen I, Zammit PS, Heslop L, Petrie A, Partridge TA, Morgan JE. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005; 122:289-301; PMID:16051152; http://dx.doi.org/10.1016/j.cell.2005.05.010
143. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, Partridge T, Buckingham M. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 309:2064-7; PMID:16141372; http://dx.doi.org/10.1126/science.1114758
144. Kuang S, Gillespie MA, Rudnicki MA. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2008; 2:22-31; PMID:18371418; http://dx.doi.org/10.1016/j.stem.2007.12.012
145. Lluís F, Perdiguero E, Nebreda AR, Muñoz-Cánoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol 2006; 16:36-44; PMID:16325404; http://dx.doi.org/10.1016/j.tcb.2005.11.002
146. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell 2000; 102:777-86; PMID:11030621; http://dx.doi.org/10.1016/S0092-8674(00)00066-0
147. Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. EMBO J 2004; 23:3430-9; PMID:15282552; http://dx.doi.org/10.1038/sj.emboj.7600346
148. Mozzetta C, Consalvi S, Saccone V, Forcales SV, Puri PL, Palacios D. Selective control of Pax7 expression by TNF-activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. Cell Cycle 2011; 10:191-8; PMID:21220942; http://dx.doi.org/10. 4161/cc.10.2.14441
149. Buckingham M. Skeletal muscle progenitor cells and the role of Pax genes. C R Biol 2007; 330:530-3; PMID:17631448; http://dx.doi.org/10.1016/j.crvi.2007. 03.015
150. Juan AH, Derfoul A, Feng X, Ryall JG, Dell'Orso S, Pasut A, Zare H, Simone JM, Rudnicki MA, Sartorelli V. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev 2011; 25:789-94; PMID:21498568; http://dx.doi.org/10.1101/gad.2027911
151. Merlino G, Helman LJ. Rhabdomyosarcoma - working out the pathways. Oncogene 1999; 18:5340-8; PMID:10498887; http://dx.doi.org/10.1038/sj.onc. 1203038
152. Otten AD, Firpo EJ, Gerber AN, Brody LL, Roberts JM, Tapscott SJ. Inactivation of MyoD-mediated expression of p21 in tumor cell lines. Cell Growth Differ 1997; 8:1151-60; PMID:9372238
153. Sebire NJ, Malone M. Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 2003; 56:412-6; PMID:12783965; http://dx.doi.org/10.1136/jcp.56.6.412
154. Saab R, Spunt SL, Skapek SX. Chapter 7 - Myogenesis and Rhabdomyosarcoma: The Jekyll and Hyde of Skeletal Muscle. 1st ed. Elsevier Inc; 2011.
155. Mahoney SE, Yao Z, Keyes CC, Tapscott SJ, Diede SJ. Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 2012; 7:400-8; PMID:22419069; http://dx.doi.org/10.4161/epi.19463
156. Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle 2012; 11:3828-36; PMID:22983009; http://dx.doi.org/10.4161/cc.22025
157. Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'agnese A, Walters ZS, Verginelli F, De Sio L, et al.; The Polycomb group. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 2013; PMID:24213577; http://dx.doi.org/10.1038/onc.2013.471
158. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, Raney RB, Womer RB, Parham DM, Qualman SJ, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999; 17:3487-93; PMID:10550146
159. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RKM, Tan PBO, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050-63; PMID:17437993; http://dx.doi.org/10.1101/gad.1524107
160. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012; 78:138-43; PMID:22925699; http://dx.doi.org/10.1016/j.lungcan. 2012.08.003
161. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492:108-12; PMID:23051747; http://dx.doi.org/10.1038/nature11606
162. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 2013; 12:2113-9; PMID:23759589; http://dx.doi.org/10.4161/cc.25163
163. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012; 109:21360-5; PMID:23236167; http://dx.doi.org/10.1073/pnas.1210371110
164. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8:890-6; PMID:23023262
165. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 2013; 110:7922-7; PMID:23620515; http://dx.doi.org/10.1073/pnas.1303800110
166. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, Eckert RL. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 2011; 32:1525-32; PMID:21798853; http://dx.doi.org/10.1093/carcin/bgr171
167. Lin Y-H, Lee C-C, Chang F-R, Chang W-H, Wu Y-C, Chang J-G. 16-hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells. Life Sci 2011; 89:886-95; PMID:21983300; http://dx.doi.org/10.1016/j.lfs.2011. 09.011